'Drugs from Bugs': Bacterial effector proteins as promising biological (immune-) therapeutics

FEMS Microbiology Letters

Volumn 351, Issue 2, 2014, Pages 126-132

  Rüter, Christian ^a   Hardwidge, Philip R ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

Autoimmune disease; Cell penetrating peptides; Immune system; Virulence factor

Indexed keywords

BACTERIAL EFFECTOR PROTEIN; BACTERIAL PROTEIN; CELL PENETRATING PEPTIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN NLEB1; UNCLASSIFIED DRUG; VIRULENCE FACTOR; YERSINIA OUTER PROTEIN;

ANTIBODY RESPONSE; ARTICLE; BACTERIAL VIRULENCE; CELL TRANSPORT; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TYPE III SECRETION SYSTEM;

BACTERIA (MICROORGANISMS);

AUTOIMMUNE DISEASE; CELL-PENETRATING PEPTIDES; IMMUNE SYSTEM; VIRULENCE FACTOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BACTERIA; BACTERIAL PROTEINS; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOLOGIC FACTORS;

EID: 84896723256     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/1574-6968.12333     Document Type: Article

References (52)

1. Afonin S, Frey A, Bayerl S, Fischer D, Wadhwani P, Weinkauf S & Ulrich AS (2006) The cell-penetrating peptide TAT(48-60) induces a non-lamellar phase in DMPC membranes. Chemphyschem 7: 2134-2142.
2. Alberts B, Johnson A, Lewis J, Raff M, Roberts K & Walter P (2002) Molecular Biology of the Cell, 5th edn. Garland Science, New York, NY.
3. Ashida H, Kim M, Schmidt-Supprian M, Ma A, Ogawa M & Sasakawa C (2010) A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKgamma to dampen the host NF-kappaB-mediated inflammatory response. Nat Cell Biol 12: 66-73; sup pp 61-69.
4. Beutler B (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430: 257-263.
5. Cooper GS & Stroehla BC (2003) The epidemiology of autoimmune diseases. Autoimmun Rev 2: 119-125.
6. Cornelis GR (2002) The Yersinia Ysc-Yop virulence apparatus. Int J Med Microbiol 291: 455-462.
7. Dai S, Hirayama T, Abbas S & Abu-Amer Y (2004) The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 279: 37219-37222.
8. Dean P (2011) Functional domains and motifs of bacterial type III effector proteins and their roles in infection. FEMS Microbiol Rev 35: 1100-1125.
9. Gao X, Wan F, Mateo K et al. (2009) Bacterial effector binding to ribosomal protein s3 subverts NF-kappaB function. PLoS Pathog 5: e1000708.
10. Gao X, Wang X, Pham TH, Feuerbacher LA, Lubos ML, Huang M, Olsen R, Mushegian A, Slawson C & Hardwidge PR (2013) NleB, a bacterial effector with glycosyltransferase activity, targets GAPDH function to inhibit NF-κB activation. Cell Host Microbe 13: 87-99.
11. Garcia-Angulo VA, Deng W, Thomas NA, Finlay BB & Puente JL (2008) Regulation of expression and secretion of NleH, a new non-locus of enterocyte effacement-encoded effector in Citrobacter rodentium. J Bacteriol 190: 2388-2399.
12. Gerke C, Falkow S & Chien YH (2005) The adaptor molecules LAT and SLP-76 are specifically targeted by Yersinia to inhibit T cell activation. J Exp Med 201: 361-371.
13. Ghosh S & Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl): S81-S96.
14. Haraga A & Miller SI (2003) A Salmonella enterica serovar typhimurium translocated leucine-rich repeat effector protein inhibits NF-kappa B-dependent gene expression. Infect Immun 71: 4052-4058.
15. Hawiger J (1997) Cellular import of functional peptides to block intracellular signaling. Curr Opin Immunol 9: 189-194.
16. Hoebe K, Du X, Georgel P et al. (2003) Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424: 743-748.
17. Jung E, Lee NK, Kang SK, Choi SH, Kim D, Park K, Choi K, Choi YJ & Jung DH (2012) Identification of tissue-specific targeting peptide. J Comput Aided Mol Des 26: 1267-1275.
18. Keshet Y & Seger R (2010) The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol 661: 3-38.
19. Kim DW, Lenzen G, Page AL, Legrain P, Sansonetti PJ & Parsot C (2005) The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. P Natl Acad Sci USA 102: 14046-14051.
20. Langel Ü (2005) Cell-Penetrating Peptides: Methods and Protocols. CRC Press, Taylor & Francis Group, Boca Raton, p. 241.
21. Langel Ü (2010) Handbook of Cell-Penetrating Peptides. CRC Press, Taylor & Francis Group, Boca Raton, p. 401.
22. Li H, Xu H, Zhou Y, Zhang J, Long C, Li S, Chen S, Zhou JM & Shao F (2007) The phosphothreonine lyase activity of a bacterial type III effector family. Science 315: 1000-1003.
23. Li S, Zhang L, Yao Q et al. (2013) Pathogen blocks host death receptor signalling by arginine GlcNAcylation of death domains. Nature 501: 242-246.
24. Matsumoto H & Young GM (2009) Translocated effectors of Yersinia. Curr Opin Microbiol 12: 94-100.
25. McInnes IB & Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7: 429-442.
26. McPhee JB, Mena P & Bliska JB (2010) Delineation of regions of the Yersinia YopM protein required for interaction with the RSK1 and PRK2 host kinases and their requirement for interleukin-10 production and virulence. Infect Immun 78: 3529-3539.
27. Mi Z, Lu X, Mai JC, Ng BG, Wang G, Lechman ER, Watkins SC, Rabinowich H & Robbins PD (2003) Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium. Mol Ther 8: 295-305.
28. Michgehl S, Heusipp G, Greune L, Rüter C & Schmidt MA (2006) Esp-independent functional integration of the translocated intimin receptor (Tir) of enteropathogenic Escherichia coli (EPEC) into host cell membranes. Cell Microbiol 8: 625-633.
29. Mukherjee S, Keitany G, Li Y, Wang Y, Ball HL, Goldsmith EJ & Orth K (2006) Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science 312: 1211-1214.
30. Newton HJ, Pearson JS, Badea L et al. (2010) The type III effectors NleE and NleB from enteropathogenic E. coli and OspZ from Shigella block nuclear translocation of NF-kappaB p65. PLoS Pathog 6: e1000898.
31. Okuda J, Toyotome T, Kataoka N, Ohno M, Abe H, Shimura Y, Seyedarabi A, Pickersgill R & Sasakawa C (2005) Shigella effector IpaH9.8 binds to a splicing factor U2AF(35) to modulate host immune responses. Biochem Biophys Res Commun 333: 531-539.
32. O'Sullivan B, Thompson A & Thomas R (2007) NF-kappa B as a therapeutic target in autoimmune disease. Expert Opin Ther Targets 11: 111-122.
33. Pearson JS, Riedmaier P, Marches O, Frankel G & Hartland EL (2011) A type III effector protease NleC from enteropathogenic Escherichia coli targets NF-kappaB for degradation. Mol Microbiol 80: 219-230.
34. Pearson JS, Giogha C, Ong SY et al. (2013) A type III effector antagonizes death receptor signalling during bacterial gut infection. Nature 501: 247-251.
35. Persson C, Carballeira N, Wolf-Watz H & Fällman M (1997) The PTPase YopH inhibits uptake of Yersinia, tyrosine phosphorylation of p130Cas and FAK, and the associated accumulation of these proteins in peripheral focal adhesions. EMBO J 16: 2307-2318.
36. Rang HP, Dale MM, Ritter JM & Moore PK (2003) Pharmacology, 5th edn. Churchill Livingstone, Edinburgh, New York.
37. Rohde JR, Breitkreutz A, Chenal A, Sansonetti PJ & Parsot C (2007) Type III secretion effectors of the IpaH family are E3 ubiquitin ligases. Cell Host Microbe 1: 77-83.
38. Rüter C, Buss C, Scharnert J, Heusipp G & Schmidt MA (2010) A newly identified bacterial cell-penetrating peptide that reduces the transcription of pro-inflammatory cytokines. J Cell Sci 123: 2190-2198.
39. Scharnert J, Greune L, Zeuschner D, Lubos ML, Alexander Schmidt M & Rüter C (2013) Autonomous translocation and intracellular trafficking of the cell-penetrating and immune-suppressive effector protein YopM. Cell Mol Life Sci 70: 4809-4823.
40. Schellekens H (2010) The immunogenicity of therapeutic proteins. Discov Med 9: 560-564.
41. Skov L, Beurskens FJ, Zachariae CO et al. (2008) IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol 181: 669-679.
42. Smedby KE, Askling J, Mariette X & Baecklund E (2008) Autoimmune and inflammatory disorders and risk of malignant lymphomas-an update. J Intern Med 264: 514-527.
43. Stewart KM, Horton KL & Kelley SO (2008) Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem 6: 2242-2255.
44. Terme M, Ullrich E, Delahaye NF, Chaput N & Zitvogel L (2008) Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 9: 486-494.
45. Viboud GI & Bliska JB (2005) Yersinia outer proteins: role in modulation of host cell signaling responses and pathogenesis. Annu Rev Microbiol 59: 69-89.
46. Viboud GI, Mejía E & Bliska JB (2006) Comparison of YopE and YopT activities in counteracting host signalling responses to Yersinia pseudotuberculosis infection. Cell Microbiol 8: 1504-1515.
47. Von Pawel-Rammingen U, Telepnev MV, Schmidt G, Aktories K, Wolf-Watz H & Rosqvist R (2000) GAP activity of the Yersinia YopE cytotoxin specifically targets the Rho pathway: a mechanism for disruption of actin microfilament structure. Mol Microbiol 36: 737-748.
48. Wan F, Weaver A, Gao X, Bern M, Hardwidge PR & Lenardo MJ (2011) IKKbeta phosphorylation regulates RPS3 nuclear translocation and NF-kappaB function during infection with Escherichia coli strain O157:H7. Nat Immunol 12: 335-343.
49. Yadav D & Sarvetnick N (2003) Cytokines and autoimmunity: redundancy defines their complex nature. Curr Opin Immunol 15: 697-703.
50. Zhang L, Ding X, Cui J et al. (2012) Cysteine methylation disrupts ubiquitin-chain sensing in NF-kappaB activation. Nature 481: 204-208.
51. Zhou H, Monack DM, Kayagaki N, Wertz I, Yin J, Wolf B & Dixit VM (2005) Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-kappa B activation. J Exp Med 202: 1327-1332.
52. Zhu Y, Li H, Long C, Hu L, Xu H, Liu L, Chen S, Wang DC & Shao F (2007) Structural insights into the enzymatic mechanism of the pathogenic MAPK phosphothreonine lyase. Mol Cell 28: 899-913.